Literature DB >> 6321094

Beta-lactamase stability of cefoxitin in comparison with other beta-lactam compounds.

H C Neu.   

Abstract

The beta-lactamase stability of cefoxitin, the second-generation cephamycin compound, was compared with that of cefamandole, cefoperazone, cefotaxime, moxalactam, carbenicillin, and piperacillin. Unlike cefamandole, cefoperazone, carbenicillin, and piperacillin, cefoxitin was not hydrolyzed by the common plasmid beta-lactamases, TEM-1, TEM-2, OXA-2, and SHV-1. Cefoxitin and moxalactam were the only agents stable to all chromosomal beta-lactamases, whereas cefamandole, cefoperazone, cefotaxime, carbenicillin, and piperacillin were destroyed by cephalosporinases of Proteus vulgaris and Bacteroides fragilis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6321094     DOI: 10.1016/0732-8893(83)90006-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

Review 1.  Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Authors:  George G Zhanel; Christopher D Lawson; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Andrew Denisuik; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

2.  Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis.

Authors:  G J Cuchural; F P Tally; J R Storey; M H Malamy
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

3.  Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases.

Authors:  Wei Ke; Christopher R Bethel; Jodi M Thomson; Robert A Bonomo; Focco van den Akker
Journal:  Biochemistry       Date:  2007-04-19       Impact factor: 3.162

Review 4.  Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Authors:  Philippe Lagacé-Wiens; Andrew Walkty; James A Karlowsky
Journal:  Core Evid       Date:  2014-01-24

Review 5.  Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Authors:  Jose A Hidalgo; Celeste M Vinluan; Nishaal Antony
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.